This article is part of the Research Topic Novel Extracellular Signalling Mechanisms in Bone


Front. Endocrinol., 19 September 2012 |

Purinergic signaling in bone

  • Department of Human Metabolism, The Mellanby Centre for Bone Research, The University of Sheffield, Sheffield, UK

Purinergic signaling in bone was first proposed in the early 1990s with the observation that extracellular ATP could modulate events crucial to the normal functioning of bone cells. Since then the expression of nearly all the P2Y and P2X receptors by osteoblasts and osteoclasts has been reported, mediating multiple processes including cell proliferation, differentiation, function, and death. This review will highlight the most recent developments in the field of purinergic signaling in bone, with a special emphasis on recent work resulting from the European Framework 7 funded collaboration ATPBone, as well as Arthritis Research UK and Bone Research Society supported projects.

Keywords: ATP, purinergic signaling, P2Y, P2X, osteoblast, osteoclast, bone, osteoporosis

Citation: Rumney RMH, Wang N, Agrawal A and Gartland A (2012) Purinergic signaling in bone. Front. Endocrin. 3:116. doi: 10.3389/fendo.2012.00116

Received: 29 April 2012; Paper pending published: 21 May 2012;
Accepted: 04 September 2012; Published online: 19 September 2012.

Edited by:

Deborah Mason, Cardiff University, UK

Reviewed by:

Elena Adinolfi, University of Ferrara, Italy
Gudrun Stenbeck, Brunel University, UK

Copyright: © 2012 Rumney, Wang, Agrawal and Gartland. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.

*Correspondence: Alison Gartland, Department of Human Metabolism, The Mellanby Centre for Bone Research, The University of Sheffield, Beech Hill Road, Sheffield, South Yorkshire S10 2RX, UK. e-mail: